Greifs\u00adwald \u2014 Great success for Nebula Bioci\u00addes GmbH, three inves\u00adtors decide to invest in the Greifs\u00adwald-based start-up. This brings the start-up a signi\u00adfi\u00adcant step closer to its goal of obtai\u00adning appr\u00adoval for and laun\u00adching the highly effec\u00adtive disin\u00adfec\u00adtant Sporo\u00adsan\u00ae on the market.<\/p>\n
With a total invest\u00adment of 1.6 million euros, the start-up Nebula Bioci\u00addes, foun\u00added in 2019, can now take off: the appr\u00adoval of the novel disin\u00adfec\u00adtion process Sporo\u00adsan\u00ae is supported by High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF), Mittel\u00adst\u00e4n\u00addi\u00adsche Betei\u00adli\u00adgungs\u00adge\u00adsell\u00adschaft Meck\u00adlen\u00adburg-Vorpom\u00admern mbH (MBMV) and a stra\u00adte\u00adgic inves\u00adtor from the clea\u00adning and disin\u00adfec\u00adtion equip\u00adment sector as part of a seed financing.<\/p>\n
\u201cWe are very plea\u00adsed to have a strong busi\u00adness part\u00adner and, with HTGF and MBMV, two expe\u00adri\u00aden\u00adced and network-strong finan\u00adcial inves\u00adtors on board,\u201d said Dr. J\u00f6rn Winter, CEO of Nebula Biocides<\/p>\n
Toge\u00adther with his colle\u00adague Dr. Ansgar Schmidt-Bleker, also foun\u00adder and mana\u00adging direc\u00adtor of Nebula Bioci\u00addes GmbH, he had disco\u00advered the novel disin\u00adfec\u00adtion process in 2016. As part of their work at the Leib\u00adniz Insti\u00adtute for Plasma Rese\u00adarch and Tech\u00adno\u00adlogy e.V. (INP), the physi\u00adcists iden\u00adti\u00adfied the subs\u00adtance peroxi\u00adni\u00adtrite acid as an effec\u00adtive agent and deve\u00adlo\u00adped the Sporo\u00adsan\u00ae process on this basis. In this process, two start\u00ading compon\u00adents react with each other for a short time and have a highly disin\u00adfec\u00adting effect during this period.<\/p>\n
Sporo\u00adsan\u00ae not only kills bacte\u00adria and viru\u00adses; even stub\u00adborn bacte\u00adrial spores have no chance of survi\u00adval thanks to the new process,\u201d says Schmidt-Bleker, empha\u00adsi\u00adzing the broad effi\u00adcacy of the disin\u00adfec\u00adtant. In the future, this will also prevent infec\u00adtions with the dange\u00adrous hospi\u00adtal germ Clos\u00adtri\u00addio\u00adides diffi\u00adcile, which leads to severe diar\u00adrhea and is often fatal, espe\u00adci\u00adally in previously ill pati\u00adents. The Greifs\u00adwald rese\u00adar\u00adchers have thus achie\u00adved a breakth\u00adrough \u2014 to date there is no disin\u00adfec\u00adtant in the world with a compa\u00adra\u00adbly strong and rapid effect that is at the same time envi\u00adron\u00admen\u00adtally friendly and gentle in use.<\/p>\n
The signi\u00adfi\u00adcance and poten\u00adtial of the active ingre\u00addi\u00adent were also reco\u00adgni\u00adzed by the three inves\u00adtors, whose parti\u00adci\u00adpa\u00adtion will now make it possi\u00adble to finance the studies requi\u00adred for approval.<\/p>\n
\u201cWe are very proud to welcome Nebula Bioci\u00addes to our port\u00adfo\u00adlio with their distinctly disrup\u00adtive chemis\u00adtry inno\u00adva\u00adtion. The under\u00adly\u00ading tech\u00adno\u00adlogy promi\u00adses to create nume\u00adrous sustainable appli\u00adca\u00adtion oppor\u00adtu\u00adni\u00adties,\u201d Dr. Niko\u00adlaus Raupp, Invest\u00adment Mana\u00adger at High-Tech Gr\u00fcnderfonds<\/p>\n
With the help of the inves\u00adtors, the company, which now consists of a team of five, can pursue two paths at once: First, it is aiming for appr\u00adoval as a biocide, so that Sporo\u00adsan will be available to ever\u00adyone as a hand and surface disin\u00adfec\u00adtant from 2028. In paral\u00adlel, the Nebula team is working inten\u00adsi\u00advely on solu\u00adti\u00adons for the spori\u00adci\u00addal repro\u00adces\u00adsing of medi\u00adcal devices with the aim of marke\u00adting the disin\u00adfec\u00adtant itself as a medi\u00adcal device. With the stra\u00adte\u00adgic inves\u00adtor, an indus\u00adtrial part\u00adner has alre\u00adady been found who would like to use Sporo\u00adsan\u00ae for its products; market launch is expec\u00adted in 2024. Howe\u00adver, the start-up is alre\u00adady recei\u00adving inqui\u00adries from other inte\u00adres\u00adted compa\u00adnies from a wide range of indus\u00adtries every week, which only further unders\u00adcores the scope of Greifs\u00adwal\u00add\u2019s inno\u00adva\u00adtion in the health\u00adcare, phar\u00admaceu\u00adti\u00adcal and food industries.<\/p>\n
About Nebula Bioci\u00addes GmbH<\/strong> About Mittel\u00adst\u00e4n\u00addi\u00adsche Betei\u00adli\u00adgungs\u00adge\u00adsell\u00adschaft Meck\u00adlen\u00adburg-Vorpom\u00admern mbH<\/strong> Greifs\u00adwald \u2014 Great success for Nebula Bioci\u00addes GmbH, three inves\u00adtors decide to invest in the Greifs\u00ad\u00adwald-based start-up. This brings the start-up a signi\u00adfi\u00adcant step closer to its goal of obtai\u00adning appr\u00adoval for and laun\u00adching the highly effec\u00adtive disin\u00adfec\u00adtant Sporo\u00adsan\u00ae on the market. With a total invest\u00adment of 1.6 million euros, the start-up Nebula Bioci\u00addes, founded [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":38262,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1369,1373],"tags":[],"class_list":["post-40230","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-investors","category-venture-capital-en"],"yoast_head":"\n
\nNebula Bioci\u00addes GmbH was foun\u00added in 2019 as a spin-off from the Leib\u00adniz Insti\u00adtute for Plasma Science and Tech\u00adno\u00adlogy e.V. (INP) by the scien\u00adtists Dr. J\u00f6rn Winter, Dr. Ansgar Schmidt-Bleker and the direc\u00adtor of INP Prof. Dr. Klaus-Dieter Welt\u00admann in Greifs\u00adwald. With the aim of provi\u00adding compre\u00adhen\u00adsive protec\u00adtion against infec\u00adtious agents, the company deve\u00adlops appli\u00adca\u00adtion-orien\u00adted disin\u00adfec\u00adtion solu\u00adti\u00adons that relia\u00adbly kill not only bacte\u00adria and viru\u00adses but also stub\u00adborn bacte\u00adrial spores. www.nebula-biocides.de<\/p>\n
\nMittel\u00adst\u00e4n\u00addi\u00adsche Betei\u00adli\u00adgungs\u00adge\u00adsell\u00adschaft Meck\u00adlen\u00adburg-Vorpom\u00admern mbH (MBMV) has been support\u00ading regio\u00adnal SMEs with project finan\u00adcing for over 28 years. It closes finan\u00adcing gaps and at the same time puts the equity base of small and medium-sized enter\u00adpri\u00adses on a broa\u00adder footing and makes it possi\u00adble to realize promi\u00adsing ideas or promi\u00adsing busi\u00adness stra\u00adte\u00adgies. MBMV is also a relia\u00adble part\u00adner for start-ups and entre\u00adpre\u00adneurs. www.mbm\u2011v.de<\/p>\n","protected":false},"excerpt":{"rendered":"